Traditional batch production methods in biopharmaceuticals manufacturing require human intervention to process materials and can take months to complete the final formulated product, resulting in high costs and prolonged delivery of therapeutics to patients. Factors that influence the cost include the complexity of the mRNA sequence/structure, yield and purity of the manufacturing process, batch size, facility overheads, and regulatory compliance.

Join this session to learn:

• How continuous manufacturing can help reduce costs, increase productivity, and improve product consistency.
• How the integration of process analytical technologies (PAT) and AI-driven computation techniques is a key enabler of continuous mRNA manufacturing.